Revenue
2018
2019
2020
2021
2022
2023
2024
2025
PRECISION BIOSCIENCES INC (DTIL)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.3M | $68.7M | $48.7M | $25.1M | $115.5M | $24.3M | $22.2M | $10.9M |
| Research & development | $54.2M | $59.6M | $53.4M | $46.1M | $115.2M | $98.1M | $82.4M | $45.1M |
| Operating expenses | $86.4M | $94.9M | $92.5M | $87.4M | $154.9M | $134.1M | $109.4M | $58.8M |
| Operating income | −$52.1M | −$26.2M | −$43.7M | −$62.3M | −$39.4M | −$109.8M | −$87.2M | −$47.9M |
| EBITDAderived | −$50.7M | −$22.8M | −$36.9M | −$54.5M | −$30.4M | −$101.1M | −$81.9M | −$45.6M |
| Net income | −$45.7M | $7.2M | −$61.3M | −$111.6M | −$30.6M | −$109.0M | −$92.9M | −$46.0M |
| Basic EPSper diluted share | -$3.56 | $1.05 | -$15.96 | -$38.10 | -$0.52 | -$2.09 | -$2.21 | -$2.92 |
| Diluted EPSper diluted share | -$3.56 | $1.04 | -$15.96 | -$38.10 | -$0.52 | -$2.09 | -$2.21 | -$2.92 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 18, 2026Form 4 · 10b5-1 | Amoroso MichaelPresident and CEO | SellCommon Stock | 20.6K | $3.84 | $78.9K | 243.4K |
| Feb 18, 2026Form 4 · 10b5-1 | Kelly John AlexanderChief Financial Officer | SellCommon Stock | 8.1K | $3.84 | $31.3K | 125.9K |
| Feb 18, 2026Form 4 · 10b5-1 | Scimeca DarioGeneral Counsel and Secretary | SellCommon Stock | 4.9K | $3.84 | $18.9K | 56.5K |
| Feb 18, 2026Form 4 · 10b5-1 | SMITH J. JEFFERSONChief Research Officer | SellCommon Stock | 4.9K | $3.84 | $18.9K | 121.9K |
| Jan 22, 2026Form 4 · 10b5-1 | Amoroso MichaelPresident and CEO | SellCommon Stock | 34.8K | $4.17 | $145.1K | 196.2K |